These results should serve as the basis for future clinical studies to distinguish patients with estrogen receptor-positive metastatic breast cancer who might be best treated with endocrine therapy alone versus those who should receive endocrine therapy plus an ancillary treatment, such as CDK4/6, mTOR, or PIK3CA inhibitors. Each of these has been shown to complement endocrine therapy, but each is associated with additional side effects and costs."
DANIEL F. HAYES, MD
Professor in Breast Cancer and Clinical Director of Breast Oncology at the University of Michigan Comprehensive Cancer Center
Our results imply that the DiviTum® TKa test is prognostic both at baseline and on treatment with CDK4/6 inhibitors. This is intriguing as there is not a test that predict CDK4/6 inhibitor efficacy in the clinic at this time. Circulating tumor DNA (ctDNA) analysis has shown great promise but often expensive and not used to monitor disease clinically."
CYNTHIA MA, MD, PhD
Professor of Medicine and Medical Oncologist Washington University,
St. Louis
These results are highly encouraging and highlight the potential of the DiviTum® TKa test to evaluate treatment efficacy already during the first weeks of therapy, and afterwards to monitor the disease.” The results from our study support using DiviTum TKa to monitor efficacy during treatment and predict response to a CDK4/6 inhibitor, a standard therapy for women with metastatic breast cancer. It is interesting to learn that the DiviTum® TKa test can identify progression many months ahead of imaging."
LUCA MALORNI, MD, PhD
Medical Oncologist,
Prato Hospital, Italy
The results from our study support using the DiviTum® TKa test to monitor efficacy during treatment and predict response to palbociclib (a CDK4/6 inhibitor), a standard therapy for women with metastatic breast cancer. It is interesting to learn that DiviTum® TKa can identify progression many months ahead of imaging."
JAIRAM KRISHNAMURTHY, MD